Core Viewpoint - The announcement highlights the exclusive licensing agreement between the company and Madrigal Pharmaceuticals for the global development, production, and commercialization of the oral small molecule GLP-1 receptor agonist SYH2086 [1] Group 1: Agreement Details - The company grants Madrigal exclusive rights to develop, produce, and commercialize SYH2086 globally while retaining rights to develop and sell other oral small molecule GLP-1 receptor agonists in China [1] - The total consideration for the agreement can reach up to $2.075 billion, which includes an upfront payment of $120 million and potential milestone payments of up to $1.955 billion based on development, regulatory, and commercial achievements [1] - Additionally, the company is entitled to receive a high double-digit sales royalty based on the annual net sales of SYH2086 [1]
石药集团(01093.HK)与Madrigal达成20.75亿美元重磅合作，创新药出海再突破